AR Grade Sodium Fluoride Powder / NaF Anticoagulant In Glucose Blood Collection Tube

product name sodium fluoride (NaF)

Molecular weight 41.99

Properties White powder, toxic. Soluble in water, the solution is corrosive to glass. Almost insoluble in ethanol.

Executive standard GB/T1264-1997 (national standard)

Use Anti-glycemic decomposition agent, used in combination with potassium oxalate, for blood glucose testing.

(One-time use of vacuum blood collection tube additives).

Specification 500g/bottle

Product packaging

Usage and Dosage

The concentration should be 1 mg-3 mg (0.003934 mol/L-0.0111 mol/L) of potassium oxalate monohydrate per ml of blood.

Sodium fluoride 2 mg-4 mg (0.0476 mol/L-0.0952 mol/L).

The recommended dosage is: sodium fluoride (2.5-3mg/mL blood) / potassium oxalate (2.0mg/mL blood)

additive code: NFX.

Storage Sealed and moisture-proof.

Shelf life two years

AR Grade NaF Anticoagulant Powder for Sodium Fluoride Glucose Tube for blood collection

Sodium Fluoride Glucose Tube in grey top. It is widely used to collect blood for glucose determinations. Sodium fluoride is used in glucose tube as glycolysis inhibitor to preserve glucose when combined with anticoagulant EDTA K2.

Sodium Fluoride Glucose Tube in grey top

Glucose tube container a series of EDTA anticoagulant agents. By using an inhibitor and special inside treatment, the blood sample can be preserved for a longer period without its original status being changed and the metabolism of blood cells almost cease. It is widely used to collect blood for glucose determinations. Sodium fluoride is used in glucose tube as glycolysis inhibitor to preserve glucose when combined with anticoagulant EDTA K2.

Sodium citrate

In 1941 sodium fluoride (NaF) containing tubes were introduced into laboratory practice for blood collection for glucose measurement.5 NaF has been known to have an antiglycolytic effect that inhibits glycolysis by erythrocytes. The use of these tubes appeared to be suitable for blood collection when laboratory practice was not streamlined and there was a long delay in blood separation following collection, a practice that continued, and was not questioned or revisited, for more than five decades.

Taking into consideration that NaF action in inhibiting enolase enzyme in glycolytic pathway is slow, as it will start after nearly four hours from blood collection, its effect has recently been critically questioned.6,7 The most recent guidelines in 2011 for the diagnosis and management of diabetes mellitus approved by the American Diabetes Association (ADA) no longer recommends the use of NaF to control glycolysis, with the recommendation to stop its use.8 Gambino9 criticized the false belief that NaF is an effective inhibitor of glycolysis. Bruns10 also questioned whether fluoride-containing tubes are still needed for blood glucose testing in his editorial support of the study by Fernandez et al,11 which reported no difference in glucose values for blood specimens collected in serum separator tubes (SST) and NaF tubes that were separated within two hours of collection.